Stephen Duane Oetgen, Director at Arxis, Inc. (ARXS), bought 30,357 shares at $28.00 ($700K) on 2026-04-17, disclosed to the SEC on 2026-04-20.
Director Stephen Duane Oetgen purchased 25,000 shares for $700,000, marking the largest insider purchase in Arxis's history. This significant capital commitment suggests the director sees strong value in the aerospace and defense stock following recent analyst upgrades.
The stock is currently trading 4.05% below its 52-week high of $39.24 and 6.81% above its 52-week low of $35.25, reflecting a year-to-date decline of 9.34% despite recent analyst bullishness.
Analysts initiated coverage with Buy ratings on May 11, 2026, citing the company's acquisition-driven industrial compounder model and exposure to defense spending growth. Additionally, the insider's purchase of $700,000 represents the largest trade in the company's history, signaling strong conviction from leadership.
The stock trades at a forward P/E of 51.42, which is a high valuation multiple for the sector. Furthermore, short interest represents 2.39% of the float, indicating a potential headwind if the stock fails to sustain its recent rally.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 5,357 | $0 | 0.0% |
| 2 | $28.00 | 25,000 | $700K | 100.0% |
| Total | $23.06 avg | 30,357 | $700K | 100% |